Listen on the go
  • Saudi Arabia Prescribing Information
    • Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Naji Aljohani

    Endocrinology and Thyroid Oncology Consultant, Obesity, Endocrine and Metabolic Center, King Fahad Medical City, & Associate Professor, Alfaisal University, Riyadh, Saudi Arabia

    Prof. Naji Aljohani is a Consultant in Endocrinology and Thyroid Oncology at the Obesity, Endocrine and Metabolic Center, King Fahad Medical City. He also serves as Associate Professor at Alfaisal University.

    Disclosures: Honoraria from Chiesi Farmaceutici S.p.A.
    Prof. Naji Kholaif

    Cardiology and Echocardiography Consultant, King Faisal Specialist Hospital and Research Center, & Adjunct Assistant Professor, Alfaisal University, Riyadh, Saudi Arabia

    Prof. Naji Kholaif is a Cardiology and Echocardiography Consultant at King Faisal Specialist Hospital and Research Center. He also serves as an Adjunct Assistant Professor at Alfaisal University.

    After completing his residency training at Drexel University in Philadelphia, Prof. Kholaif pursued further specialization in Cardiology at the University of Alberta in Edmonton, Canada. He went on to earn a Master’s degree in Translational Medicine from the same institution. Prof. Kholaif holds American and Canadian board certifications in Internal Medicine, Cardiology, and Echocardiography.

    Prof. Kholaif’s research interests are focused on Familial Hypercholesterolemia, Cardio-oncology, and Valvular Heart Disease in Pregnancy. He has recently published a registry on patients with Homozygous Familial Hypercholesterolemia.

    Disclosures: Honoraria from Chiesi Farmaceutici S.p.A.
    touchCARDIO touchCARDIO
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Atherosclerosis

    US ATHEROSCLEROSIS PARTNER

    An Introduction to Atherosclerosis

    Atherosclerosis is defined as the build-up of plaque in the arteries, causing the narrowing of arteries and leading to the majority of heart attacks and strokes. Statin monotherapy has long been established as the gold-standard treatment, however the treatment landscape has grown over recent years with the introduction of new lipid-lowering therapies including fibrates, ezetimibe and PCSK-9 inhibitors. Further research and large-scale clinical trials are required to better compare their efficacy and safety with standard statin therapy.

    Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Atherosclerosis Content

    touchEXPERT BRIEFING
    Treating to Target in Homozygous Familial Hypercholesterolemia
    For HCPs in: HCPs in Saudi Arabia
    View Time: 16 mins Sponsored content

    Experts review best practice in treating homozygous familial hypercholesterolemia (HoFH).

     

    Code: LOM/SA/003
    Date of Preparation: March 2024
    Cardiovascular Disease, Atherosclerosis
    Watch Time: 30 mins
    touchIN CONVERSATION
    Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
    Prof. Kausik Ray, Dr. med. Mahir Karakas Translations available:

    Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias

    Learning objectives
    Learning Objectives
    • Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
    • Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
    • Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
    Atherosclerosis
    Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden
    Venkat S Manubolu, Matthew J Budoff, Suvasini Lakshmanan

    Heart International. 2022;16(1):2–11 DOI: https://doi.org/10.17925/HI.2022.16.1.2

    Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable residual risk for cardiovascular disease (CVD) still exists despite reducing LDL cholesterol.2 Beyond traditional risk factors, other […]

    Atherosclerosis
    Signs You Could Be Suffering from Peripheral Artery Disease

    Dr Jacob White is an interventional radiologist with over 15 years of experience. He currently serves as Medical Director at USA Vein Clinics, Vascular and Fibroid Centers and is on staff at the Jacobi Medical Centre in NYC. Dr White is a regular contributor to numerous medical journals.      Despite being a common condition, […]

    Atherosclerosis
    Developed by Touch
    Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol
    Watch Time: 7 mins

    The TRANSLATE-TIMI 70 trial looks at the effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol. touchCARDIO spoke with Dr Brian Bergmark (Brigham and Women’s Hospital, Boston, MA) about the use of vupanorsen and the safety and efficacy of the TRANSLATE-TIMI 7 trial. Questions: What is vupanorsen and what is […]

    Atherosclerosis
    Developed by Touch
    Paul Ridker, ACC 2022: Secondary analysis of the CANTOS trial of the inflammatory hypothesis of atherothrombosis and chronic kidney disease
    Watch Time: 6 mins

    The CANTOS trial assessed the differential impact of residual inflammatory risk and residual cholesterol risk among atherosclerosis patients with and without chronic kidney disease. touchCARDIO spoke to Prof Paul Ridker (Harvard University, Boston, MA, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘Secondary Analysis of the CANTOS Trial: […]

    Atherosclerosis
    Charalambos Antoniades, ESC 2021 – The Fat Attenuation Index
    Watch Time: 8 mins 45

    Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the fat attenuation index and its use in clinical decision making from the virtual ESC Congress 2021. Questions Can you tell us a little about the fat attenuation index (FAI) and how it can be […]

    Atherosclerosis
    Charalambos Antoniades, ESC 2021 – High-sensitivity C-reactive Protein, Perivascular Adipose Tissue and Atherosclerosis
    Watch Time: 2 mins 32

    Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the use of high-sensitivity C-reactive protein as a biomarker in clinical decision making, and the role of perivascular adipose tissue in the pathogenesis of atherosclerosis from the virtual ESC Congress 2021. Questions What is the […]

    Atherosclerosis, Cardiovascular Disease
    Stephen Nicholls, ESC 2021 – the HUYGENS Study
    Watch Time: 6 mins 20

    Prof. Stephen Nicholls (Professor of Cardiology, Monash University, Melbourne, Australia) kindly shared his thoughts on the impact of PCSK9 inhibitors on lipid-lowering therapy, the effects of statins on coronary atherosclerotic plaques and the HUYGENS study from the virtual ESC Congress 2021. Questions What has been the impact of PCSK9 inhibitors on lipid-lowering therapy, and what […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchCARDIO is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup